Astrazeneca (AZN) Common Equity (2009 - 2026)

Astrazeneca (AZN) has reported Common Equity for 18 consecutive years, with $47.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 15.2% year-over-year to $47.4 billion; the TTM figure through Mar 2026 stood at $47.4 billion (up 15.2% YoY), while the FY2025 annual figure was $48.7 billion, up 19.45% from the prior year.
• Common Equity came in at $47.4 billion for Q1 2026 at Astrazeneca, down from $48.7 billion in the prior quarter.
• The five-year high for Common Equity was $48.7 billion in Q4 2025, with the low at $35.2 billion in Q3 2022.
• Average Common Equity over 5 years is $40.0 billion, with a median of $39.2 billion recorded in 2023.
• The largest YoY upside for Common Equity was 218.55% in 2022 against a maximum downside of 11.92% in 2022.
• Year by year, Common Equity stood at $37.1 billion in 2022, then advanced by 5.69% to $39.2 billion in 2023, then advanced by 4.14% to $40.8 billion in 2024, then increased by 19.45% to $48.7 billion in 2025, then slipped by 2.74% to $47.4 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $47.4 billion, $48.7 billion, and $46.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.